Clinical Trials Browser

OTHER × lirilumab × Head & Neck × Clear all

NCT03341936 2025-06-18

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

Phase 2 Active not recruiting

29 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell